Trial Details
AuthorisedBasic Information
| Clinical ID | c3076 |
|---|---|
| Identifier | EUCTR2014-001919-39-NL |
| Trial Title | Lengthening Adalimumab Dosing Interval in IBD patients in long term__remission, the LADI study |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Inflammatory bowel disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20] |
| Interventions | Trade Name: Humira Product Name: adalimumab Pharmaceutical Form: Solution for injection in pre-filled pen |
Participant Information
| Sponsor | Erasmus MC |
|---|---|
| City | - |
| Country/Region | Netherlands |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | Not Available |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |